EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long–term trends in ceftolozane–tazobactam susceptibility among gram–negative pathogens in the United States: a nine–year SMART analysis (2016–2024)

Mark G Wise iD, Karri A Bauer, John S Esterly, Fakhar Siddiqui, Katherine Young, Mary R Motyl, Daniel F Sahm

JAC-Antimicrobial Resistance · 02.07.2026 · 8 (4)

DOI: 10.1093/jacamr/dlag134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 07.07.2026. Verfasst von Mark G Wise und 6 weiteren Autor:innen. Beteiligte Einrichtung: IHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme, Merck & Co., Inc..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate trends in the susceptibility of clinical Enterobacterales and Pseudomonas aeruginosa from the USA to ceftolozane/tazobactam.

Methods

The SMART surveillance programme collected 30 658 Enterobacterales and 7454 P. aeruginosa isolates from 37 unique clinical sites in the USA from 2016 to 2024. Nine sites contributed isolates each year. MICs were determined by broth microdilution testing and interpreted using 2025 CLSI breakpoints. Ceftolozane/tazobactam nonsusceptible Enterobacterales were examined for β-lactamase carriage.

Results

Overall, 93.9% and 95.8% of clinical isolates of Enterobacterales and P. aeruginosa were susceptible to ceftolozane/tazobactam, respectively. Considering all participating sites, annual percent susceptible values for ceftolozane/tazobactam against Enterobacterales ranged from 95.3% (2018, n = 3657) to 92.0% (2024, n = 3249) with a statistically significant decreasing trend (P < 0.001; Cochran-Armitage test). Limiting analysis solely to the nine clinical sites that participated in each year confirmed this trend [range: 94.5% susceptible (2019, n = 1609) to 91.4% susceptible (2024, n = 1544); P = 0.007]. Including all sites, P. aeruginosa percent susceptible values for ceftolozane/tazobactam remained consistent from 2016 (95.0%) to 2024 (95.0%) [range: 94.5% (2017, n = 991) to 96.9% (2020, n = 817)]. However, considering solely the consistently contributing sites, the rate of ceftolozane/tazobactam susceptibility increased [P = 0.013; range: 91.9% (2017, n = 371) to 96.4% (2024, n = 391)]. The incidence of NDM metallo-β-lactamase and CTX-M ESBLs among ceftolozane/tazobactam nonsusceptible Enterobacterales each exhibited a statistically significant increasing trend.

Conclusions

From 2016 to 2024, ceftolozane/tazobactam activity against US P. aeruginosa remained consistently high; however, a trend of marginally decreasing susceptibility to ceftolozane/tazobactam among Enterobacterales was observed, likely associated with increased incidence of NDM- and CTX-M-producers.

Autor:innen und Institutionen

  • IHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA.
  • Merck & Co., Inc., Rahway, NJ, USA.

ORCID-Profile: Mark G Wise

Förderung

  • Merck Sharp & Dohme
  • Merck & Co., Inc.

Zitieren

APA

Wise, M. G., Bauer, K. A., Esterly, J. S., Siddiqui, F., Young, K., Motyl, M. R., & Sahm, D. F. (2026). Long–term trends in ceftolozane–tazobactam susceptibility among gram–negative pathogens in the United States: a nine–year SMART analysis (2016–2024). JAC-Antimicrobial Resistance, 8(4). https://doi.org/10.1093/jacamr/dlag134

Vancouver

Wise MG, Bauer KA, Esterly JS, Siddiqui F, Young K, Motyl MR, et al. Long–term trends in ceftolozane–tazobactam susceptibility among gram–negative pathogens in the United States: a nine–year SMART analysis (2016–2024). JAC-Antimicrobial Resistance. 2026;8(4). doi:10.1093/jacamr/dlag134

BibTeX
@article{Wise2026,
  author = {Wise, Mark G and Bauer, Karri A and Esterly, John S and Siddiqui, Fakhar and Young, Katherine and Motyl, Mary R and Sahm, Daniel F},
  title = {Long–term trends in ceftolozane–tazobactam susceptibility among gram–negative pathogens in the United States: a nine–year SMART analysis (2016–2024)},
  journal = {JAC-Antimicrobial Resistance},
  year = {2026},
  volume = {8},
  number = {4},
  doi = {10.1093/jacamr/dlag134}
}
Kostenlos starten →